

AIMS-SK
Module 2 - OPIOID USE DISORDER
Friday, April 19, 2024 | Virtual



UNIVERSITY OF SASKATCHEWAN
College of Medicine
DIVISION OF CONTINUING MEDICAL EDUCATION
CME@U.SASK.EDU



| | | |
|--------------------------|---|---|
| 7:45 AM | Attendee Sign-In | |
| 8:00 AM | Welcome, Treaty Land Acknowledgment, Virtual Housekeeping | |
| Plenary Session 1 | | |
| 8:05AM - 8:50AM | 35 10 | <p>Patient Assessment and Suitability Dr. Victoria Tian or Dr. Andrew Yang At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> •Demonstrate proper clinical assessment. •Discuss nuances of informed consent for patients living with opioid use disorder starting on opioid agonist therapy, including potential side effects. •Strategies for communication and collaboration with family physician and other allied health care professionals. <p>Q & A</p> |
| Plenary Session 2 | | |
| 8:55AM - 9:55AM | 45 15 | <p>Corrections and Transition of Care Dr. Jess Melle At the end of this session learners will be able to:</p> <ol style="list-style-type: none"> 1. Identify the unique challenges of managing substance use disorders within the corrections environment. 2. Coordinate interprofessional team efforts to ensure seamless transitional care for individuals released from the correctional system. 3. Advocate for an inclusive, respect-based approach in dealing with individuals living with substance use disorders within the corrections system and during post-release transitions. <p>Q & A</p> |
| Break (15minutes) | | |
| Plenary Session 3 | | |
| 10:10AM - 10:40AM | 20 10 | <p>Whats's on the street Sgt Greg Smith At the end of this session learners will be able to:</p> <ol style="list-style-type: none"> 1. Identify and classify common street drugs according to their chemical composition, including opioids, stimulants, depressants, hallucinogens, and cannabinoids. 2. Describe the physical characteristics of various street drugs, such as color, odor, taste, texture, and packaging methods. 3. Explain the common methods of administration for street drugs, including oral ingestion, inhalation, injection, and transdermal absorption. |
| Plenary Session 4 | | |
| 10:45AM - 11:45PM | 45 15 | <p>Opioid Agonist Therapy: Benefits Dr. Larissa Kiesman At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> •Develop an organized approach to OAT •Compare and contrast buprenorphine / naloxone and methadone •Learn the different approaches to induction •Understand dosage adjustments for stabilization, missed doses, and tapering •Place OAT in the context of a Recovery Oriented System of Care <p>Q & A</p> |
| LUNCH BREAK (45 mins) | | |
| Plenary Session 5 | | |
| 12:30PM - 1:00PM | 20 10 | <p>Urine Drug Screen to Optimize Treatment Dr. Morris Markentin At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> •Understand the benefits and limitations of urine drug screening. •Offer tips for reducing tampering & false/inaccurate results. •Incorporate urine drug screening in practice. <p>Q & A</p> |
| Plenary Session 6 | | |
| 1:05PM - 1:35PM | 20 10 | <p>Carries: Balancing Safety and Access Dr. Erin Hamilton At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> •Describe how carries can be put into practice. •Review the provincial standards and guidelines <p>Q & A</p> |
| Plenary Session 7 | | |
| 1:40PM - 2:40PM | 45 15 | <p>Role of the Pharmacist in OAT Matt Manz At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> •Discuss the role of trauma informed care in pharmacy practice. •Explain the medication coverage for opioid agonist therapy in Saskatchewan. •List how pharmacists can make opioid agonist therapy more accessible and feasible for patients. •Describe how pharmacists can monitor and support patients on opioid agonist therapy, including review of potential drug interactions. •Explain the importance of pharmacists' involvement during transitions in care . •List potential harm reduction strategies pharmacists can provide. <p>Q & A</p> |
| Break (15 minutes) | | |
| Plenary Session 7 | | |
| 2:55PM - 3:25PM | 20 10 | <p>OAT in Pregnancy & Breastfeeding Dr. Morris Markentin At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> •Review substance use disorder and addiction in pregnancy. •Consider opioid agonist therapy dosing for pregnant and breastfeeding patients. •Describe strategies for supporting antepartum and post-partum patients. <p>Q & A</p> |
| Plenary Session 8 | | |
| 3:30PM - 4:00PM | 20 10 | <p>Day in the life of an OAT Provider Jeannie Coe At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> •Discuss cases from experts working in addictions medicine. •Present early day expectations for prescribers starting to work as an opioid agonist prescriber. <p>Q & A</p> |
| 4:00PM - 4:05PM | 5 | Complete Survey for Certificate & Closing Remarks |

*Schedule is subject to change